Cargando…
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
Background: The innovative injection of interleukin 17 A (IL-17A) monoclonal antibody QX002N is being developed to treat active ankylosing spondylitis and plaque psoriasis in adults. Objective: This study investigated the pharmacokinetics (PKs), pharmacodynamics (PDs) safety, tolerability, and immun...
Autores principales: | Wu, Min, Zhang, Hong, Li, Qianqian, Chen, Hong, Fang, Min, Yang, Lizhi, Ding, Yanhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931745/ https://www.ncbi.nlm.nih.gov/pubmed/35310892 http://dx.doi.org/10.3389/fphar.2021.794054 |
Ejemplares similares
-
A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
por: Gao, Lei, et al.
Publicado: (2021) -
First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
por: Ma, Tingting, et al.
Publicado: (2022) -
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023) -
Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015) -
A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra(®)) in Chinese healthy subjects
por: Zhang, Hong, et al.
Publicado: (2021)